• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    duloxetine api market Companies

    ID: MRFR/HC/6238-CR
    99 Pages
    Rahul Gotadki
    April 2019

    Duloxetine is an active pharmaceutical ingredient (API) used in the production of medications that treat depression, anxiety, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain. Several pharmaceutical companies are involved in the manufacturing and supply of Duloxetine API.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Duloxetine API Market Research Report - Global Forecast till 2032 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the duloxetine api market


    Duloxetine API Key Companies*Disclaimer: List of key companies in no particular orderLatest Duloxetine API Companies Update


    • October 2023: Teva Pharmaceutical Industries, the world's largest Duloxetine API supplier, has partnered with Sanofi, a French pharmaceutical company, to create a medication to treat inflammatory bowel disease. Teva's anti-TL1A medication will receive $1.5 billion in funding from Sanofi, a market leader in immunology. We won't know any intermediate findings until the second half of 2024, as the medicine is still in phase 2 testing at this point. Phase 3 studies for a medicine that treats Crohn's disease and ulcerative colitis are scheduled to commence in 2025, with a possible commercial release in the year 2028.




    • October 2023: Agreements to purchase minority holdings in Ezerx Health Tech Ltd. and Agatsa Software Ltd. were signed by Sun Pharmaceutical Industries Ltd. in October 2023, making it the top provider of Duloxetine API. The investments are in complementary industries, and the corporation has agreed to buy a minority ownership in the entities. The pharmaceutical behemoth will purchase 37.76% of Ezerx Health Tech and 4.04% of Agatsa Software. After initially agreeing to buy 26.09% of Agatsa Software, Sun Pharma has now boosted its stake in the company by 4.04 percent. After this transaction, the pharmaceutical firm will hold 30.13 percent of a digital diagnostic devices firm still in the early stages of development.




    • October 2023: Sun Pharmaceutical Industries Ltd, the world's largest producer of Duloxetine API, announced that deuruxolitinib, an oral experimental medication for the treatment of people with moderate to severe alopecia areata, had its new drug application authorized by the US health agency. Sun Pharma has submitted a new medication application to the US Food and medication Administration (USFDA) for consideration of its 8mg twice daily dose of deuruxolitinib, the company said in a statement.


    List of Duloxetine API Key companies in the market

    • Teva Pharmaceutical Industries Ltd

    • Sun Pharmaceutical Industries Ltd

    • Aurobindo Pharma

    • Lupin

    • ZydusCadila

    • Eli Lilly and Company

    • Hetero

    • Apotex Inc.

    • Shionogi Inc.

    • Zhejiang Huahai Pharmaceutical Co., Ltd